Travere Therapeutics (TVTX) EBITDA: 2011-2025
Historic EBITDA for Travere Therapeutics (TVTX) over the last 13 years, with Sep 2025 value amounting to $25.5 million.
- Travere Therapeutics' EBITDA rose 146.99% to $25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.6 million, marking a year-over-year increase of 74.61%. This contributed to the annual value of -$320.2 million for FY2024, which is 191.20% down from last year.
- Per Travere Therapeutics' latest filing, its EBITDA stood at $25.5 million for Q3 2025, which was up 300.13% from -$12.7 million recorded in Q2 2025.
- Travere Therapeutics' EBITDA's 5-year high stood at $150.9 million during Q3 2023, with a 5-year trough of -$136.5 million in Q1 2024.
- In the last 3 years, Travere Therapeutics' EBITDA had a median value of -$59.3 million in 2024 and averaged -$41.8 million.
- In the last 5 years, Travere Therapeutics' EBITDA tumbled by 3,653.67% in 2021 and then skyrocketed by 321.09% in 2023.
- Travere Therapeutics' EBITDA (Quarterly) stood at -$51.6 million in 2021, then slumped by 33.76% to -$69.0 million in 2022, then decreased by 27.44% to -$88.0 million in 2023, then soared by 32.56% to -$59.3 million in 2024, then surged by 146.99% to $25.5 million in 2025.
- Its EBITDA stands at $25.5 million for Q3 2025, versus -$12.7 million for Q2 2025 and -$42.0 million for Q1 2025.